Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study BSA and nintedanib reduction/discontinuation

Main Article Content

Yukihiro Toi
Yuichiro Kimura
Yutaka Domeki
Sachiko Kawana
Tomoiki Aiba
Hirotaka Ono
Mari Asou
Kyoji Tsurumi
Kana Suzuki
Hisashi Shimizu
Jun Sugisaka
Ryohei Saito
Keisuke Terayama
Yosuke Kawashima
Atsushi Nakamura
Shinsuke Yamanda
Yoshihiro Honda
Shunichi Sugawara

Keywords

body surface area, discontinuation, dose reduction, idiopathic pulmonary fibrosis, nintedanib

Abstract

Background: We have often encountered adverse events requiring dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Objectives: The objectives of this study were to clarify the incidence of dose reduction and/or discontinuation following the commercialization of nintedanib and to investigate predictors of dose reduction and/or discontinuation of nintedanib at our hospital. Methods: We retrospectively identified 25 patients who had received nintedanib 150 mg twice daily at Sendai Kousei Hospital and categorized them into two groups according to whether they had or had not required dose reduction and/or discontinuation and sought to identify predictors of dose reduction and/or discontinuation. Results: Seventeen patients developed adverse events, which included diarrhea (n=10, 44%), hepatotoxicity (n=7, 28%), and anorexia (n=2, 16%). No adverse event-related deaths occurred during the study period. Patients who required dose reduction and/or discontinuation were significantly older than those who did not (72 years vs 67 years; P=0.047). Body surface area (BSA) was significantly lower in the group that needed dose reduction and/or discontinuation than in the group that did not (1.63 m2 vs. 1.78 m2; P=0.028). Multivariate logistic regression revealed that the association of low BSA with dose reduction and/or discontinuation was statistically significant. Conclusions: A low BSA was associated with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Further studies in larger patient samples are needed to validate these findings.

a

Downloads

Download data is not yet available.
Abstract 168 | PDF Downloads 146